Post Reply
621-640 of 1587
I hold Rex bro not tis but I seriously think tis company is picking up. True bro hope we can Huat
togethet😀 👍 . Happy weekends
togethet😀 👍 . Happy weekends
gregtan123 ( Date: 28-Feb-2020 19:48) Posted:
|
I got no position. to be fair, if Monday ALL medical up, we ALL Huat together!
Power1 ( Date: 28-Feb-2020 19:41) Posted:
|
1Q 2020 result will see more improvement
Around 14 may 2020 1Q 2020 released
DYODD
Around 14 may 2020 1Q 2020 released
DYODD
benny100 ( Date: 28-Feb-2020 19:33) Posted:
|
They who denied the profit of tis company is in state of
denial because of their short positions😂 😂
denial because of their short positions😂 😂
benny100 ( Date: 28-Feb-2020 19:33) Posted:
|
Fy2019 Revenue increased from 6.14 to 21.53
fy2019 loss decreased from 18.89 to 11.54
4Q 2019 EBITDA turn positive
fy2019 loss decreased from 18.89 to 11.54
4Q 2019 EBITDA turn positive
Justice888 ( Date: 28-Feb-2020 19:17) Posted:
|
Ah Tan ah! Do do your homework pls. COV critically patient will end up with renal failure and
Clearbridge company dealings with renal test and equipments facilities. More or less
the company revenue will be boost because of it. Pls read and read again until u understand hor🤣
Clearbridge company dealings with renal test and equipments facilities. More or less
the company revenue will be boost because of it. Pls read and read again until u understand hor🤣
gregtan123 ( Date: 28-Feb-2020 18:37) Posted:
|
A summary of the results:
Results are negative. Revenue increase by so much yet still post losses. ( 6.135m to 21.53m increase in revenue vs losses of 11.54m). This shows that management has difficulty converting revenue steam into profits as the cost is too high. Hence model of management is unsustainable. (For example, management and staff remuneration maybe too high. Taking shareholders equity to pay for this cost will end up driving shareholders away as they won?t be foolish enough to inject more funds just to enrich the management.)
Cash flow issues:
Cash on hand is $13.56mil but needs to repay $4.797mil this year and thereafter another $16.85mil. Company is short of $8.087mil cash. A cash call could be due soon so expect share dilution. Worryingly, even after a 250% increase in revenue, the company is still making losses of $11.5mil so I wonder how much cash the company can still burn before asking for cash from shareholders again. Nav is downgraded from 9.74c to 8.69c.
Verdict: Dividend is at the end of long tunnel. Possibility of cash call is high. Best to avoid.
Results are negative. Revenue increase by so much yet still post losses. ( 6.135m to 21.53m increase in revenue vs losses of 11.54m). This shows that management has difficulty converting revenue steam into profits as the cost is too high. Hence model of management is unsustainable. (For example, management and staff remuneration maybe too high. Taking shareholders equity to pay for this cost will end up driving shareholders away as they won?t be foolish enough to inject more funds just to enrich the management.)
Cash flow issues:
Cash on hand is $13.56mil but needs to repay $4.797mil this year and thereafter another $16.85mil. Company is short of $8.087mil cash. A cash call could be due soon so expect share dilution. Worryingly, even after a 250% increase in revenue, the company is still making losses of $11.5mil so I wonder how much cash the company can still burn before asking for cash from shareholders again. Nav is downgraded from 9.74c to 8.69c.
Verdict: Dividend is at the end of long tunnel. Possibility of cash call is high. Best to avoid.
That' s what my broker said the revenue is power and the target price increase👍
happyboy588 ( Date: 28-Feb-2020 19:13) Posted:
|
What about the profit?
Power1 ( Date: 28-Feb-2020 19:10) Posted:
|
Why said Clearbridge result is bad. I see it?s great. It?s Q4 actually already turned to profit.
gregtan123 ( Date: 28-Feb-2020 18:37) Posted:
|
Result so shiok💪 🏻 💪 🏻 💪 🏻 HUAT AH!!!! HO SEY LIAO
WBdisciple ( Date: 28-Feb-2020 18:40) Posted:
|
Boosted by Strong Growth from Accretive Healthcare Acquisitions, Clearbridge Posts Record Revenue of S$21.53 Million in FY2019
&bull Revenue from the Group&rsquo s medical clinics/centres increased 103.7% to S$5.97 million in FY2019, mainly due to the contributions from the newly acquired nine dental clinics in Singapore in August 2019 (with a first right of refusal to acquire another 6 dental clinics)
&bull Revenue from the Group&rsquo s healthcare systems increased 384.7% to S$15.56 million in FY2019, of which IGM Labs was the main revenue contributor despite being acquired only in May 2019 and an additional JO contract pending novation
&bull Excluding fair value changes in associate and derivative financial instruments & non-recurring operating expenses, the Group has recorded another quarter of positive adjusted EBITDA of S$0.55 million in 4Q2019
Asia&rsquo s integrated healthcare company, Clearbridge Health Limited (&ldquo Clearbridge&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ) (" 明 策 集 团 &rdquo ), is pleased to announce another set of record revenue of S$21.53 million achieved for the full year ended 31 December 2019 (&ldquo FY2019&rdquo ), which was driven by strong contributions from its healthcare acquisitions during FY2019.
The Group&rsquo s healthcare systems business unit, in particular its laboratory services and renal care services in Indonesia, was the major revenue contributor in FY2019 with revenue increasing by 384.7% or S$12.35 million to S$15.56 million during the period under review.
Adopting a Public-Private-Partnership Model to scale its healthcare services operations in Indonesia, Clearbridge currently manages a total of 49 hospital joint operation contracts (&ldquo JOs&rdquo ) in Indonesia serving close to 4 million patients per year, primarily in the area of renal care (through PT Tirta Medika Jaya (&ldquo TMJ&rdquo ) which was acquired in April 2018) and pathology (through PT Indo Genesis Medika (&ldquo IGM Labs&rdquo ) which was acquired in May 2019) at public and private hospitals (ranging from Class A to Class C) in Indonesia.
The renal care services and laboratory testing services offered by TMJ and IGM Labs respectively are reimbursed through the Indonesia health coverage program.
TMJ is currently operating 21 renal care centres under JO with hospitals in Indonesia. In addition, there are another 16 renal care centres that are currently under construction, with the potential of additional revenue contribution once these renal care centres are in operation.
For IGM Labs, it is operating 12 diagnostics laboratories in hospitals with another JO contract that is in the process of being novated to IGM Labs that undertakes more than 7 million pathology tests a year. Notably, IGM Labs has diagnostics laboratories in 6 of the largest Class A hospitals, out of 16 Class A hospitals in Indonesia.
Revenue from the Group&rsquo s medical centres and clinics business unit increased 103.7% to S$5.97 million, which was mainly driven by the contributions of S$2.35 million from the nine dental clinics, operating under the &ldquo Dental Focus&rdquo brand name, which were acquired in September 2019.
Commenting on the FY2019 results, Mr Jeremy Yee (余 斌 ), Executive Director and Chief Executive Officer of Clearbridge, said, &ldquo Over the past two years, through a combination of organic and inorganic initiatives, we have transformed Clearbridge into a high-growth, broad-based healthcare group with a differentiated market approach in Southeast Asia.
Our performance in FY2019 shows that we are at an inflection point of our EBITDA-focused strategy in the healthcare industry.
Building on this strong momentum, we will continue to strengthen our market position and execute on strategic growth initiatives to deliver sustainable growth and unlock value for shareholders.&rdquo
Soon everyone will realise the next Rex from Medical Counter is Medtecs!! Clearbridge not only result bad, do you all realise no mention on Covid-19? So speculators the last few weeks bought say clearbrideg tech can help all wrong. Now if still waant to play medical come Medtec! No more casino stock liao!
Also compare Medtec even with Bigger Cap of Riverstone! Compare their results AND forward looking statement. Now all we need is UOB, POEMs lift restrictions OR Pandemic OR one brokerage release BUY Report. IF 1 of the 3 factors hit: 0.12 bare min. If 2 factors: 0.15 bare min. If ALL 3: multibagger at 21 cents. Same as Rex 52-week high! Huat ah
Also compare Medtec even with Bigger Cap of Riverstone! Compare their results AND forward looking statement. Now all we need is UOB, POEMs lift restrictions OR Pandemic OR one brokerage release BUY Report. IF 1 of the 3 factors hit: 0.12 bare min. If 2 factors: 0.15 bare min. If ALL 3: multibagger at 21 cents. Same as Rex 52-week high! Huat ah
guards80 ( Date: 28-Feb-2020 18:33) Posted:
|
Revenue up ... exp up... losses up
guards80 ( Date: 28-Feb-2020 18:33) Posted:
|
Loss making. Nav downgrade.
guards80 ( Date: 28-Feb-2020 18:25) Posted:
|
Result out liaoz
BIOLIDICS TO DEVELOP ITS PROPRIETARY CANCER DIAGNOSTICS SOLUTIONS IN CHINA WITH NEW LABORATORY COLLABORATION
- As compared to a tissue biopsy that is invasive to the patient, Biolidics& rsquo proprietary cancer diagnostics solutions aim to be a cheaper, safer and simpler alternative
- Cancer generally requires long periods of treatment and cancer diagnostic tests are continuously required to monitor the effectiveness of the cancer treatment throughout the various stages of a patient' s cancer journey
- The incidence of cancer in China has increased at 3.9% annually with an average number of over 10,000 patients diagnosed with cancer per day in China in 2015
- Potential for Biolidics to expand its revenue channels once its proprietary cancer diagnostics solutions are clinically validated in China, which is targeted in the second half of 2020
Deploying its own resources and integrating its patented technology, which separates cancer cells from the blood sample, with other downstream analytical platforms, Biolidics aims to obtain the clinical validation of its proprietary cancer diagnostic solutions in the second half of 2020.
After which, the Group will launch and progressively market the cancer diagnostic solutions to hospitals across China. As of February 2019, there had been a total of 33,000 hospitals in China.
With increasing incidence and mortality, cancer is the leading cause of death in China and it has become a major public health problem. Cancer generally requires long periods of treatment and as patients undergo cancer drug treatments, there is a need to monitor the effectiveness of the treatment throughout the various stages of a patient' s cancer journey, such as cancer screening, cancer staging and post-cancer monitoring.
With a growing demand for minimally invasive procedures in cancer diagnostics, Biolidics& rsquo solutions, which uses blood sample from patients, aims to provide cancer patients in China with accurate, cost-effective, and real-time diagnoses to improve their treatment outcomes and quality of life.
Hold coz once it bound back it will GAP up fiercely.
Shortist at work and they have to buy back🤪
Shortist at work and they have to buy back🤪
Varifas ( Date: 28-Feb-2020 15:02) Posted:
|
CUT CUT CUT
Still positive? Anyone can explain ?